Alaunos Therapeutics
TCRT
146 hedge funds and large institutions have $242M invested in Alaunos Therapeutics in 2020 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 54 increasing their positions, 32 reducing their positions, and 23 closing their positions.
69% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 32
29% more call options, than puts
Call options by funds: $4.41M | Put options by funds: $3.42M
4% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 23
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.01% less ownership
Funds ownership: 0.32% → 0.31% (-0.01%)
1% less funds holding
Funds holding: 148 → 146 (-2)
40% less capital invested
Capital invested by funds: $404M → $242M (-$162M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
+$16.7M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$12.9M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.84M |
| 4 |
BlackRock
New York
|
+$5.01M |
| 5 |
Renaissance Technologies
New York
|
+$2.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.74M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.87M |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$901K |
| 4 |
D.E. Shaw & Co
New York
|
-$639K |
| 5 |
Squarepoint
New York
|
-$626K |
TCRT Hedge Fund Activity: Q1 2020 in Review
146 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q1 2020, worth a combined $242M — down 40% from $404M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new TCRT positions and 23 closed out — a net gain of 1 holder — while 54 added to existing stakes and 32 trimmed.
The largest buyer was Discovery Capital Management, adding an estimated $16.7M. The largest seller was Millennium Management, cutting an estimated $4.74M.
- 146 institutional investors held Alaunos Therapeutics (TCRT) as of Q1 2020, down from 148 in Q4 2019.
- Funds reported $242M of Alaunos Therapeutics stock for Q1 2020, down 40% quarter-over-quarter.
- 24 funds opened new Alaunos Therapeutics positions in Q1 2020 and 23 closed out, a net change of +1 holder.
- The largest Alaunos Therapeutics buyer in Q1 2020 was Discovery Capital Management, an estimated $16.7M added.
- The largest Alaunos Therapeutics seller in Q1 2020 was Millennium Management, an estimated $4.74M sold.
Based on aggregated 13F filings for Q1 2020.